Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron R Hansen

Showing results (121-130 of 159) with videos related to

Pageof 16
Sort By:
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
Journal of Geriatric Oncology|March 6, 2021
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysisDaniel V Araujo, J Connor Wells, Aaron R Hansen, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumabGeoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell CarcinomaAaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II TrialNeil E Fleshner, Rashid K Sayyid, Aaron R Hansen, et al.
Pageof 16

Showing results (121-130 of 159) with videos related to

Sort By:
Pageof 16
The Journal of Urology|December 27, 2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database ConsortiumKosuke Takemura, Vishal Navani, Matthew S Ernst, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 8, 2022
Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunctionPei Jye Voon, Eric X Chen, Helen X Chen, et al.
Cancer|February 1, 2024
Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma DatabaseKripa Guram, Jiaming Huang, Christian Mouchati, et al.
Clinical Genitourinary Cancer|January 8, 2026
Attrition Rates in Metastatic Renal Cell Carcinoma (mRCC) Following First Line Immunotherapy-Based Treatment: Results From the International mRCC Database Consortium (IMDC)Audreylie Lemelin, Martin Zarba, Kosuke Takemura, et al.
Journal of Geriatric Oncology|March 6, 2021
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysisDaniel V Araujo, J Connor Wells, Aaron R Hansen, et al.
Journal for Immunotherapy of Cancer|June 15, 2022
Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumabGeoffrey Alan Watson, Enrique Sanz-Garcia, Wen-Jiang Zhang, et al.
European Journal of Cancer (Oxford, England : 1990)|January 17, 2019
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trialGeorg A Bjarnason, Jennifer J Knox, Christian K Kollmannsberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell CarcinomaAaron R Hansen, Carlos A Gomez-Roca, Debbie G J Robbrecht, et al.
Frontiers in Oncology|January 22, 2025
Initial clinical experience with [<sup>177</sup>Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trialAaron R Hansen, Stephan Probst, Jean-Mathieu Beauregard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II TrialNeil E Fleshner, Rashid K Sayyid, Aaron R Hansen, et al.
Pageof 16